Skip to main content
. Author manuscript; available in PMC: 2021 Feb 10.
Published in final edited form as: J Med Chem. 2018 Sep 19;62(4):1731–1760. doi: 10.1021/acs.jmedchem.8b01092

Figure 3.

Figure 3.

(A) Estimated contribution of TRKA/B/C mutations to all TRK-driven malignancies. Data is based on estimated incidence of cancers at major sites and contribution of TRK mutations at each site. It is estimated that a total of 19 552 cancers are diagnosed each year that have a TRK oncogene. Of the new cases, 55.8% (10 917) are TRKA, 42.6% are TRKC (8325), and 1.6% (310) are TRKB. Because of the limited sequencing data, the actual amount of TRK-driven tumors could be significantly greater or lower depending on robustness of sample size, sample selection, and data analysis. Also, tumors with a TRK mutation could be dependent on a separate pathway. (B) Estimated number of cancers positive for TRKA. Lung (lung adenocarcinoma), IC (intrahepatic cholangiocarcinoma), PTC (papillary thyroid cancer), and Glio (glioblastoma).